About
Novel Therapies for Hard-to-treat Resistant Cancers
MitoCareX Bio is a drug discovery company focusing on the discovery and development of novel therapies for hard-to-treat lung cancer by targeting mitochondrial transporters (SLC25 protein family).
To discover new potential drugs targeting human mitochondrial carriers, MitoCareX Bio has developed its MITOLINE algorithm and other advanced computational capabilities to generate reliable 3D models for its mitochondrial proteins of interest – a major key step for utilizing CADD. To recognize novel small molecule scaffolds interacting with their proteins of interest, it uses its advanced cloud-based computational platform to efficiently screen numerous small molecules against our 3D models. The selected hit candidates are then progressed along the pre-clinical path.
Identity
| Name | MitoCareX Bio |
|---|---|
| Slug | mitocarex-bio |
| Type / kind | startup |
| Source _id | TXzGm5dQxRybnmgzQyy0uwGuZnKuMqacplkEA1fn3ldZ2Zr1Mywscw |
Status
| Status | acquired |
|---|---|
| Status reason | Acquired by N2OFF on Mar, 2025 |
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Tel Aviv-Yafo |
| HQ address | Tel Aviv-Yafo, Israel |
Web & social
| Website | https://mitocarexbio.com/ |
|---|---|
| https://www.linkedin.com/company/81288396/ |
Classifications
Funding
| Total raised | — |
|---|---|
| Current stage | Acquired |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}